We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects (DINAMIC)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 25, 2011
Last Update Posted: May 20, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
EpicentRx, Inc.
The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies. This study will also conduct an exploratory evaluation of objective tumor response using CT or MRI.

Condition Intervention Phase
Malignant Solid Tumor Lymphomas Drug: RRx-001 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies

Resource links provided by NLM:

Further study details as provided by EpicentRx, Inc.:

Primary Outcome Measures:
  • Number, frequency and type of adverse events [ Time Frame: 92 days ]

Enrollment: 26
Study Start Date: September 2011
Study Completion Date: February 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RRx-001 Drug: RRx-001
Dose level 1 (10 mg/m2)
Drug: RRx-001
Dose Level 2 (16.7 mg/m2)
Drug: RRx-001
Dose Level 3 (24.6 mg/m2)
Drug: RRx-001
Dose Level 4 (33 mg/m2)
Drug: RRx-001
Dose Level 5 (55.0 mg/m2)
Drug: RRx-001
Dose Level 6 (83 mg/m2)

Detailed Description:
The DINAMIC (DINitroazetidines As Medications In Cancer) trial represents a provascular approach to temporarily change tumor blood flow and oxygenation. Blood supply to most tumors is poor, causing parts of tumors to have a low oxygen content which promotes aggressiveness and metastasis. The DINAMIC trial uses specific imaging techniques (including ultrasound), biopsy, and breath analysis to provide an early assessment of therapeutic activity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is male or female, aged at least 18 years.
  • Subject has a histologically or cytologically confirmed diagnosis of an advanced, malignant, incurable solid tumor(s) or lymphoma that is metastatic and/or unresectable and/or for which standard curative measures either are not applicable, or do not exist, or are no longer effective. Subjects with curative treatment options are not eligible for the protocol.
  • Subject is not receiving any active treatment for his/her malignancy (except for prostate cancer subjects receiving luteinizing hormone-releasing hormone (LHRH) agonists and antiandrogens such as: Flutamide, Dutasteride, and Finasteride).
  • Subject's Eastern Cooperative Group (ECOG) performance status is 0, 1 or 2 at Screening.
  • Subject has acceptable liver function at Screening
  • Subject has a normal serum creatinine.
  • Subject has acceptable hematologic status at Screening
  • Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least one year), and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001.

Exclusion Criteria:

  • Impaired cardiac function that in the opinion of the Investigator could interfere with the conduct of the study or could put the subject at unacceptable risk.
  • Right-to-left, bidirectional, or transient right-to-left cardiac shunts.
  • Subjects with a history of acute cerebral infarction or transient ischemic attack within 90 days prior to Study Day 1.
  • Acute myocardial infarction or acute coronary syndromes less than one year prior to enrollment.
  • Serious ventricular arrythmias or high risk for arrhythmias due to prolongation of the QT interval.
  • Subjects who experienced a major surgery, radiotherapy, or immunotherapy within the last 21 days prior to Study Day 1 (limited palliative radiation is allowed within 14 days prior to Study Day 1).
  • Chemotherapy regimens with delayed toxicity within the 28 days prior to Study Day 1 (except for nitrosourea or mitomycin C treatments within 42 days prior to Study Day 1).
  • Chemotherapy regimens given continuously or on a weekly basis that Investigator believes to have a limited potential for delayed toxicity within 14 days prior to Study Day 1.
  • Use of an investigational anti-cancer drug within 42 days prior to Study Day 1.
  • Subject has symptomatic and/or untreated central nervous system metastases and/or intracranial hypertension.
  • Subject has a known history of an active and/or an uncontrolled infection with hepatitis A or hepatitis B.
  • Subject with a known history of a positive HIV status.
  • Subjects with pulmonary edema.
  • Subjects with respiratory failure
  • Subjects with severe emphysema, pulmonary emboli, pulmonary fibrosis or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature.
  • Subjects with Raynaud's syndrome.
  • Subjects with a serious co-morbid medical condition.
  • If female, subject is pregnant and/or breastfeeding.
  • Any subject with congenital or acquired methemoglobinemia.
  • Any subject with a history of inherited anemia or hemoglobinopathy including but not limited to hereditary spherocytosis, hereditary elliptocytosis, hereditary ovalocytosis,
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01359982

United States, California
Moores University of California San Diego Cancer Center
La Jolla, California, United States, 92093
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
EpicentRx, Inc.
Principal Investigator: Jeffrey Infante, MD SCRI Development Innovations, LLC
Principal Investigator: Tony Reid, MD University of California, San Diego
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: EpicentRx, Inc.
ClinicalTrials.gov Identifier: NCT01359982     History of Changes
Other Study ID Numbers: RRx001-11-01
First Submitted: May 23, 2011
First Posted: May 25, 2011
Last Update Posted: May 20, 2015
Last Verified: May 2015

Keywords provided by EpicentRx, Inc.:
Advanced Solid Tumors
Blood flow
Nitric oxide
Dynamic contrast enhanced MRI (DCE-MRI)
Contrast Enhanced Ultrasound (CEUS)

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases